PNT 001
Alternative Names: PNT-001Latest Information Update: 28 Apr 2024
At a glance
- Originator Beth Israel Deaconess Medical Center
- Developer Pinteon Therapeutics
- Class Antibodies; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders; Traumatic brain injuries
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Traumatic-brain-injuries in USA (IV, Infusion)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(In volunteers) in USA (IV, Infusion)
- 28 Jun 2021 Beth Israel Deaconess Medical Center licensed PNT 001 to Pinteon Therapeutics, prior to June 2021